Literature DB >> 26492182

Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.

Alena Skálová1, Tomas Vanecek, Roderick H W Simpson, Jan Laco, Hanna Majewska, Martina Baneckova, Petr Steiner, Michal Michal.   

Abstract

ETV6 gene abnormalities are well described in tumor pathology. Many fusion partners of ETV6 have been reported in a variety of epithelial and hematological malignancies. In salivary gland tumor pathology, however, the ETV6-NTRK3 translocation is specific for mammary analogue secretory carcinoma (MASC), and has not been documented in any other salivary tumor type. The present study comprised a clinical and molecular analysis of 25 cases morphologically and immunohistochemically typical of MASC. They all also displayed the ETV6 rearrangement as visualized by fluorescent in situ hybridization but lacked the classical ETV6-NTRK3 fusion transcript by standard reverse-transcriptase-polymerase chain reaction. In 4 cases, the classical fusion transcript was found by more sensitive, nested reverse-transcription-polymerase chain reaction. Five other cases harbored atypical fusion transcripts as detected by both standard and nested reverse-transcription-polymerase chain reaction. In addition, fluorescent in situ hybridization with an NTRK3 break-apart probe was also performed; rearrangement of NTRK3 gene was detected in 16 of 25 cases. In 3 other cases, the tissue was not analyzable, and in 2 further cases analysis could not be performed because of a lack of appropriate tissue material. Finally, in the 4 remaining cases whose profile was NTRK3 split-negative and ETV6 split-positive, unknown (non-NTRK) genes appeared to fuse with ETV6 (ETV6-X fusion). In looking for possible fusion partners, analysis of rearrangement of other kinase genes known to fuse with ETV6 was also performed, but without positive results. Although numbers were small, correlating the clinico-pathologic features of the 4 ETV6-X fusion tumors and 5 MASC cases with atypical fusion transcripts raises the possibility of that they may behave more aggressively.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26492182     DOI: 10.1097/PAS.0000000000000537

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  48 in total

1.  Ultrastructural Characterization of Mammary Analogue Secretory Carcinoma of the Salivary Glands: A Distinct Entity from Acinic Cell Carcinoma?

Authors:  Julie Guilmette; Gunnlaugur P Nielsen; William C Faquin; Martin Selig; Vânia Nosé; Anthony W S Chi; Peter M Sadow
Journal:  Head Neck Pathol       Date:  2017-02-13

2.  Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.

Authors:  Diana Bell; Renata Ferrarotto; Li Liang; Ryan P Goepfert; Jie Li; Jing Ning; Russell Broaddus; Randal S Weber; Adel K El-Naggar
Journal:  Virchows Arch       Date:  2019-08-19       Impact factor: 4.064

Review 3.  The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Authors:  Felipe C Geyer; Fresia Pareja; Britta Weigelt; Emad Rakha; Ian O Ellis; Stuart J Schnitt; Jorge S Reis-Filho
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

4.  Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Authors:  Martin G Dalin; Alexis Desrichard; Nora Katabi; Vladimir Makarov; Logan A Walsh; Ken-Wing Lee; Qingguo Wang; Joshua Armenia; Lyndsay West; Snjezana Dogan; Lu Wang; Deepa Ramaswami; Alan L Ho; Ian Ganly; David B Solit; Michael F Berger; Nikolaus D Schultz; Jorge S Reis-Filho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

Review 5.  Newly described salivary gland tumors.

Authors:  Alena Skalova; Michal Michal; Roderick Hw Simpson
Journal:  Mod Pathol       Date:  2017-01       Impact factor: 7.842

6.  Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.

Authors:  Bin Xu; Mohamed R Haroon Al Rasheed; Cristina R Antonescu; Deepu Alex; Denise Frosina; Ronald Ghossein; Achim A Jungbluth; Nora Katabi
Journal:  Histopathology       Date:  2019-12-11       Impact factor: 5.087

7.  Regarding Dettloff et al. "Mammary Analog Secretory Carcinoma (MASC) Involving the Thyroid Gland: A Report of the First Three Cases".

Authors:  Thèrése Bocklage; Samuel Reynolds; Montasser Shaheen; Garth Olson; Marc Barry; Jin Wu
Journal:  Head Neck Pathol       Date:  2016-09-15

8.  Retrospective Study of Buccal Mucosal Salivary Neoplasms.

Authors:  Saja A Alramadhan; Sarah G Fitzpatrick; Donald M Cohen; Indraneel Bhattacharyya; Mohammed N Islam
Journal:  Head Neck Pathol       Date:  2020-06-06

Review 9.  TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors:  Shivaani Kummar; Ulrik N Lassen
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 10.  Mammary Analogue Secretory Carcinoma (MASC) of the salivary gland: A new tumor entity.

Authors:  Ivan Damjanov; Faruk Skenderi; Semir Vranic
Journal:  Bosn J Basic Med Sci       Date:  2016-04-21       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.